Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cassel MM, Halperin DT, Shelton JD, Stanton D: Risk compensation: the Achilles’ heel of innovations in HIV prevention? Br Med J 2006, 332:605–607.
Wasserheit JN: Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992, 19:61–77.
Blower SM, Gershengorn HB, Grant RM: A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000, 287:650–654.
Lui AY, Grant RM, Buchbinder SP: Preexposure prophylaxis for HIV: Unproven promise and potential pitfalls. JAMA 2006, 206:863–865.
Wilde GJS: Target Risk: Dealing with the Danger of Death, Disease, and Damage in Everyday Decisions. Toronto: PDE Publications; 1994.
Centers for Disease Control and Prevention: HIV/AIDS Prevention Topics. http://www.cdc.gov/hiv/resources/qa/ResearchRationale.htm#RRA1 . Accessed August 2, 2007.
Massad E, Coutinho FAB, Burattini MN, et al.: The impact of imperfect vaccines on the evolution of HIV virulence. Med Hypotheses 2006, 66:907–911.
Nyamathi AM, Suhadev M, Swaminathan S, Fahey JL: Perceptions of a community sample about participation in future HIV vaccine trials in South India. AIDS Behav 2007, 11:619–627.
Chesney MA, Chambers DB, Kahn JO: Risk behavior for HIV infection in participants in preventative HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:266–271.
Crosby R, DiClemente RJ, Mettey A: Correlates of recent unprotected anal sex among men having sex with men attending a large sex resort in the South. Sex Transm Dis 2003, 30:909–913.
Dhawan D, Mayer KH: Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. J Infect Dis 2006, 193:36–44.
Rader M, Marks G, Mansergh G, et al.: Preferences about the characteristics of future HIV prevention products among men who have sex with men. AIDS Educ Prev 2001, 13:149–159.
Carballo-Dieguez A, O’sullivan LF, Lin P, et al.: Awareness and attitudes regarding microbicide and nonoxynol-9 use in a probability sample of gay men. AIDS Behav 2007, 11:271–276.
Mansergh G, Marks G, Rader M, et al.: Rectal use of nonoxynol-9 among men who have sex with men. AIDS 2003, 17:905–909.
Weber J, Desai K, Darbyshire J: The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med 2005, 2:e142.
Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000, 30:970–972.
Ostrow D, Fox KJ, Chmiel JS, et al.: Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS 2002, 16:775–780.
Vanable PA, Ostrow DG, McKirnan DJ, et al.: Impact of combination therapies on HIV risk perceptions and sexual risk among HIV-positive and HIV-negative gay and bisexual men. Health Psychol 2000, 19:134–145.
Stolte IG, de Witt JBF, van Eeden A, et al.: Perceived viral load, but not actual HIV-1-RNA load, is associated with sexual risk behavior among HIV-infected homosexual men. AIDS 2004, 18:1943–1949.
DiClemente RJ, Funkhouser E, Wingood G, et al.: Protease inhibitor combination therapy and decreased condom use among gay men. South Med J 2002, 95:421–425.
Crepaz N, Hart TA, Marks G: Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004, 292:224–236.
Pinto-Neto LF, Vieira N, Soprani M, et al.: Longitudinal comparison between plasma and seminal HIV-1 viral loads during antiretroviral treatment. Rev Soc Bras Med Trop 2003, 36:689–694.
Kalichman SC, Di Berto G, Eaton LE: Associations among HIV concentration in blood plasma and semen: review and implications of empirical findings. Sex Transm Dis 2007, In press.
Kalichman SC, Cage M, Rompa D, et al.: Human immunodeficiency virus in semen and plasma: Investigation of sexual transmission risk and behavioral correlates. AIDS Res Hum Retroviruses 2001, 17:1695–1703.
Cohen MS: Thomas Parran Award lecture: transmission and prevention of transmission of HIV-1. Sex Transm Dis 2006, 33:338–341.
Jackson JB, Barnett S, Piwowar-Manning E, et al.: A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk. AIDS 2003, 17:547–553.
Veazey RS, Springer MS, Marx PA, et al.: Protection of macaques from vaginal SHIV challenges by an orally delivered CCR5 inhibitor. Nat Med 2005, 11:1293–1294.
Kalichman SC, Nachimson D, Cherry C, Williams E: AIDS treatment advances and behavioral prevention set-backs: preliminary assessment of reduced threat perceptions. Health Psychol 1998, 17:546–550.
Schechter M, do Lago R, Mendelsohn AB, et al.: Behavioral impact, acceptability, and HIV incidence among men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004, 35:519–525.
Martin JN, Roland ME, Neilands TB, et al.: Use of the postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004, 18:787–792.
Korner H, Hendry O, Kippax S: Safe sex after post-exposure prophylaxis for HIV: interventions, challenges and ambivalences of gay men. AIDS Care 2006, 18:879–887.
Johnson K, Way A: Risk factors for HIV infection in a national adult population: evidence from 2003 Kenya Demographic and Health Survey. J Acquir Immune Defic Syndr 2006, 42:627–636.
Fink A: A possible explanation for the heterosexual male infection with AIDS. N Engl J Med 1986, 314:1167.
Auvert B, Taljaard D, Lagarde E, et al.: Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 trial. PLoS Med 2005, 2:1112–1122.
Bailey RC, Moses S, Parker CB, et al.: Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomized controlled trial. Lancet 2007, 369:643–656.
Gray RH, Kigozi G, Serwadda D, et al.: Male circumcision for HIV prevention in men in Rakai, Uganda: a randomized trial. Lancet 2007, 369:657–666.
Williams BG, Lloyd-Smith JO, Gouws E, et al.: The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med 2006, 3:e262
Kahn JG, Marseille E, Auvert B: Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Med 2006, 3:e517.
Agot KE, Kiarie JN, Nguyen HQ, et al.: Male circumcision in Siaya and Bondo districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir Immune Defic Syndr 2007, 1:66–70.
Fleming DT, Wasserheit JN: From epidemiological synergy to public health policy and practice: The contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999, 75:3–17.
Weiss HA, Thomas SL, Munabi SK, Hayes RJ: Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis. Sex Transm Infect 2006, 82:101–109.
Kalichman SC, DiFonzo K, Kyomugsha F, et al.: When briefer can be better: single session approaches to HIV risk reduction interventions. Interam J Psychol 2001, 35:41–58.
Kalichman SC, Simbayi LC, Vermaak R, et al.: HIV/AIDS risk reduction counseling for alcohol using sexually transmitted infections clinic patients in Cape Town, South Africa. J Acquir Immune Defic Syndr 2007, 44:594–600.
Crosby RA, Holtgrave DR: Will sexual risk behavior increase after being vaccinated for AIDS? Int J STD AIDS 2006, 17:180–184.
Chesney MA, Chambers DB, Kahn JO: Risk behavior for HIV infection in participants in preventative HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:266–271.
Hart GJ, Williamson LM: Increase in HIV sexual risk behavior in homosexual men in Scotland, 1996–2002: prevention failure? Sex Transm Infect 2005, 81:367–372.
Kalichman SC: Post-exposure prophylaxis for HIV infection in gay and bisexual men: implications for the future of HIV prevention. Am J Prev Med 1998, 15:120–127.
Stolte IG, de Wit JBF, van Eeden A, et al.: Perceived viral load, but not actual HIV-1-RNA load, is associated with sexual risk behavior among HIV-infected homosexual men. AIDS 2004, 18:1943–1449.
Dukers NHTM, Goudsmit J, de Wit JBF, et al.: Sexual risk behavior relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS 2001, 15:369–378.
Ostrow DE, Fox KJ, Chmiel JS, et al.: Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS 2002, 16:775–780.
Martin JN, Roland ME, Neilands TB, et al.: Use of the postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004, 18:787–792.